Literature DB >> 512840

Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.

T W Guentert, N H Holford, P E Coates, R A Upton, S Riegelman.   

Abstract

Parameters describing disposition and absolute oral bioavailability of quinidine were determined in ten normal male volunteers using a specific assay. Various models were compared for their ability to describe the experimental data. An intravenous quinidine gluconate and an oral quinidine sulfate solution were administered (3.74 mg/kg quinidine base). In three subjects the intravenous and oral studies were repeated. One-, two-, and three-compartment models with zero and first-order input were fitted to the plasma concentrations. The selection of the best model was made by the Akaike information criterion and by eye. After intravenous administration, plasma concentration-time curves could be adequately described by a two-compartment model. Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1). A clearance of 4.9 +/- 1.5 ml/min/kg was observed. After oral administration, three-compartment models were needed to describe the observed data in some cases. Absorption was in most cases best described by a zero-order rather than by a first-order process. The time to peak concentration varied from 23 to 121 min, the lag time was always less than 3 min, and the mean elimination rate constant was 0.00171 min -1. The mean oral bioavailability of quinidine was 0.70 +/- 0.17.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 512840     DOI: 10.1007/bf01062532

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  19 in total

1.  Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.

Authors:  R E BALL; M SOKOLOW
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

2.  Concentrations of quinidine in blood following oral, parenteral and rectal administration.

Authors:  E M DITLEFSEN
Journal:  Acta Med Scand       Date:  1953

3.  Dose-dependence of the pharmacokinetics of quinidine.

Authors:  P Bolme; U Otto
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

4.  Quinidine elimination in patients with congestive heart failure or poor renal function.

Authors:  K M Kessler; D T Lowenthal; H Warner; T Gibson; W Briggs; M M Reidenberg
Journal:  N Engl J Med       Date:  1974-03-28       Impact factor: 91.245

5.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

6.  More on heparin lock.

Authors:  N H Holford; S Vozeh; P Coates; J R Powell; J F Thiercelin; R Upton
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

7.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

8.  Quinidine kinetics in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

9.  Absolute quinidine bioavailability.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

10.  Determination of quinidine and its major metabolites by high-performance liquid chromatography.

Authors:  T W Guentert; P E Coates; R A Upton; D L Combs; S Riegelman
Journal:  J Chromatogr       Date:  1979-01-01
View more
  24 in total

Review 1.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

2.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Population pharmacokinetics of quinidine.

Authors:  K Fattinger; S Vozeh; H R Ha; M Borner; F Follath
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

5.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

6.  The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Authors:  R A Wooding-Scott; J Smalley; J Visco; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

7.  A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.

Authors:  J Karbwang; T M Davis; S Looareesuwan; P Molunto; D Bunnag; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

8.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

9.  Bioavailability of quinidine in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

10.  Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay.

Authors:  R A Upton; R L Williams; T W Guentert; J N Buskin; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.